Prostate cancer in clinical practice. First experiences with apalutamide within the context of therapeutic program B.56

• Authors: Krzysztof Trzebiński

Abstracts

EN

The article contains a case report of patient diagnosed with castration-resistant non-metastatic prostate cancer, treated with a novel androgen receptor inhibitor – apalutamide.

Keywords

EN

non-metastatic castration-resistant prostate cancer; apalutamide; androgen receptor inhibitor

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2023
• Volume: 13
• Issue: 1
• Pages: 27-30

Dates

published

2023

Contributors

author

Krzysztof Trzebiński

• Department of Urogenital Cancer, The Maria Sklodowska-Curie Department of Urogenital Cancer, The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw

References

• Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49. http://doi.org/10.3322/caac.21660.
• Didkowska J, Wojciechowska U, Olasek P et al. Nowotwory złośliwe w Polsce w 2019 roku. Warszawa 2021.
• Smith MR, Saad F, Chowdhury S et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018; 378: 1408-18. http://doi.org/10.1056/NEJMoa1715546.
• Parker C, Castro E, Fizazi K et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31: 1119-34. http://doi.org/10.1016/j.annonc.2020.06.011.
• Howard LE, Moreira DM, De Hoedt A et al. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017; 120(5B): E80-6. http://doi.org/10.1111/bju.13856.

Identifiers

DOI

10.24292/01.OR.131316323

Biblioteka Nauki

22676841